First-in-class neurodegeneration drug nears Phase I, signaling renewed momentum in longevity-focused neuroscience.
Cambridge-based Lysoway Therapeutics has reached a milestone of readiness for human trials that many neurodegeneration startups never cross. The company announced that its lead drug candidate, LW-1017, is now Phase I-ready, with first-in-human dosing planned for May 2026 in Australia.
This may sound like a routine biotech update, but in reality, it marks a meaningful step forward in one of aging science’s most stubborn challenges: how to help the brain clear toxic waste before it accumulates into disease.
LW-1017 is designed to activate TRPML1, a tiny ion channel buried deep inside the cell’s lysosome. Think of lysosomes as the cell’s recycling centers. When they slow down with age – as they often do – damaged proteins pile up, inflammation rises and neurons begin to fail [1]. This breakdown is a common thread running through Alzheimer’s, Parkinson’s and other neurodegenerative disorders.
TRPML1 acts like a master switch for cellular cleanup. When functioning properly, it helps coordinate autophagy, the process by which cells break down and recycle damaged components, and supports overall cellular resilience under stress. As we age, TRPML1 signaling becomes less efficient, weakening the brain’s ability to maintain order.
Lysoway is placing a straightforward but ambitious bet to restore this upstream control point, and you may slow or even counteract multiple downstream pathologies at once.
Preclinical results suggest this strategy has legs. In aged models of Parkinson’s disease, LW-1017 reduced toxic alpha-synuclein buildup, preserved dopamine-producing neurons, and improved motor function. In Alzheimer’s models, the compound lowered amyloid and phosphorylated tau levels while supporting cognitive performance. Notably, these effects were seen at low oral doses, a sign that the drug efficiently reaches the brain and that Lysoway Therapeutics is crossing an historic barrier in drug development.
One reason TRPML1 has remained out of reach for so long is its location. Lysosomal ion channels are expressed throughout the body, not just in the brain. Drugs that fail to penetrate the central nervous system risk causing side effects in peripheral tissues before delivering any neurological benefit. For this reason, brain penetration isn’t a bonus, but a prerequisite.
Using a structure-guided approach, Lysoway engineered LW-1017 to cross the blood-brain barrier effectively, achieving higher exposure in the brain than in the bloodstream. This balance allows the drug to engage its target where it matters most, while maintaining wide safety margins.
The company stated that all IND-enabling studies for LW-1017 had been completed with wide safety margins, which cleared the path for human dosing.
Alongside the Phase I announcement, Lysoway also revealed the nomination of a development candidate from its TMEM175 program, another lysosomal ion channel genetically linked to Parkinson’s disease risk.
This second program is more than a pipeline update. It signals that Lysoway’s discovery engine may be reproducible, not dependent on a single lucky breakthrough. That distinction matters enormously to investors and longevity-focused stakeholders alike.
According to Yongchang Qiu, PhD, Founder and CEO of Lysoway Therapeutics, the deterioration of the autophagy-lysosomal pathway associated with aging is a primary factor leading to neurodegeneration.
Qiu noted that while lysosomal ion channels serve as vital regulatory points within this system, they have traditionally been very challenging to target with medication, especially for central nervous system conditions.
Lysoway’s progress builds on earlier validation. In August 2025, the company received a $2.93 million grant from The Michael J Fox Foundation to advance its TRPML1 program for Parkinson’s disease. The funding supported preclinical development and biomarker work, helping accelerate the path to first-in-human trials [2].
Such backing reflects growing confidence that targeting cellular cleanup could shift the trajectory of neurodegenerative disease.
Longevity science increasingly recognizes that a single failure does not drive aging, but instead cascading breakdowns in maintenance systems. Neurodegeneration is one of the most devastating consequences of that collapse.
By targeting lysosomal function, one of the cell’s most fundamental longevity mechanisms, Lysoway is operating at the intersection of neuroscience and aging biology. If successful, LW-1017 may do more than treat individual diseases. It could help preserve cognitive health by restoring the brain’s ability to care for itself.
Human trials will determine whether this promise holds up. But for now, Lysoway’s announcement offers cautious optimism in neurodegeneration research that is grounded in biology and right momentum.
[1] https://www.lysoway.com/companynews/lysoway-therapeutics-announces-phase-i-readiness-of-brain-penetrant-trpml1-agonist-lw-1017-and-nomination-of-a-tmem175-development-candidate/
[2] https://www.lysoway.com/companynews/lysoway-therapeutics-awarded-grant-from-the-michael-j-fox-foundation-to-advance-trpml1-agonist-to-treat-parkinsons-disease/
